Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Phase 2 results Meeting Abstract
| Authors: | Zamarin, D.; Odunsi, K.; Zsiros, E.; Slomovitz, B. M.; Pimentel, A.; Duska, L. R.; Reilley, M.; Nemunaitis, J. J.; Hamouda, D. M.; Patel, H.; Segal, N. H.; Pesci, G.; Holland, A.; Shohara, L.; Schwarzenberger, P. O.; Ricciardi, T.; Macri, M. J.; Ryan, A.; Jaderberg, M. E.; Venhaus, R. R. |
| Abstract Title: | Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Phase 2 results |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680300823 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.2600 |
| Notes: | Meeting Abstract: 2600 -- Meeting also held virtually -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
